Arpita Desai

MD

Genitourinary oncologist

Dr. Arpita Desai is an oncologist who specializes in caring for patients with genitourinary cancers (cancers of the genital or urinary organs). She particularly focuses on kidney and prostate cancers.

Desai is interested in developing novel imaging and treatment strategies for kidney cell cancer, with the goal of improving outcomes by personalizing therapy. Her most recent research focused on incorporating functional and molecular imaging to personalize treatment in genitourinary cancers.

Desai earned her medical degree at Rajiv Gandhi University of Health Sciences in India. She completed a residency in internal medicine at the State University of New York at Buffalo, where she served as chief resident. She completed a fellowship in medical oncology at the University of Chicago.

Desai is a member of the American Society of Clinical Oncology (ASCO) and American Association for Cancer Research. She has received a Conquer Cancer Foundation of ASCO Merit Award and Dexter S. Levy Memorial Award for her commitment to teaching and excellence in patient care.

  • Education

    Rajiv Gandhi University of Health Sciences, 2009

  • Residencies

    University at Buffalo – SUNY, Internal Medicine, 2015

  • Fellowships

    University of Chicago, Medical Oncology, 2018

  • Board Certifications

    Internal Medicine, American Board of Internal Medicine

Where I see patients (2)

    My reviews

    4.9

    Overall Experience
    186 Ratings
    About our process
    Nov 09, 2023
    Very professional
    Nov 01, 2023
    Excellent Clinician!
    Sep 18, 2023
    We love Dr. Desai.
    May 15, 2023
    Dr Arpita Desai is absolutely the best doctor I have had.
    May 06, 2023
    Dr. Desai makes me feel completely confident in my care. I am so glad that Dr. Desai is my very caring doctor.
    Mar 27, 2023
    Like I said she is very good at explaining so I understand everything very good Dr.
    Feb 02, 2023
    Dr. Desai and the entire UCSF team provide the highest level of professionalism and care.
    Nov 10, 2022
    Dr. Desai makes me feel safe. I'm glad that she is my care giver.
    Nov 06, 2022
    Dr. Desai is probably one of the easiest providers to engage. She provides excellent context an explanation that is easy to understand and is open for questions. I think she is one of the best providers I have engaged. So glad she is part of the team.
    Oct 06, 2022
    Dr Desai is an excellent doctor. I love her sense of care and concern she displays for her patient. She also seems to be very knowledgeable in her field.
    Sep 18, 2022
    I'm very impressed and appreciative of my care from Dr Desai
    Aug 28, 2022
    I have never had a bad experience always great
    Aug 07, 2022
    Great first session looking forward to working together
    Aug 05, 2022
    Dr Arpita is fabulous. She takes time to listen to all my questions and provides great feedback.
    Aug 02, 2022
    The answers I provided are exactly what I would have written about the Dr.
    May 21, 2022
    Dr Desai and her staff are terrific.

    Selected research

    Decorative Caduceus

    Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

    Evaluation of DLT of CHS-388 as a monotherapy.

    Recruiting

    Decorative Caduceus

    Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantini...

    OS of patients who achieve complete response (CR) and progressive disease (PD) from ipilimumab-nivolumab induction phase will be summarized. The stratified log-rank statistic will be the primary analysis to compare the hypothesis ...

    Recruiting

    Contact me

    Share